Notice | Nanologica

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

21 April, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 21 maj 2026, klockan 10.00, i Advokatfirman Lindahls lokaler på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 12 maj 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 15 maj

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

21 April, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 21 May 2026, at 10.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. Right to attend the meetingShareholders who wish to participate in the Annual General Meeting must: be registered in their own name in the share register maintained by Euroclear Sweden AB on Wednesday 12 May 2026, notify the Company of its participation

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 4 mars 2026, klockan 10.00, i Advokatfirman Lindahls lokaler, på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 februari 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast torsdagen den 26

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl's premises, at Smålandsgatan 16, Stockholm. Right to participate in the meeting Shareholders who wish to participate in the Extraordinary General Meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Tuesday,

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

16 April, 2025

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 22 May 2025, at 12.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: be

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

16 April, 2025

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 22 maj 2025, klockan 12.00, i Advokatfirman Lindahls lokaler på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 14 maj 2025, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 16 maj

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.